WHEL-C-101 · Moderate evidence · 7/10

anti-androgens + lifestyle for PCOS

A meta-analysis of RCTs found anti-androgens plus lifestyle superior to metformin plus lifestyle for hirsutism and SHBG in PCOS, but not superior to placebo plus lifestyle for those outcomes.

Origin · Existing drug · repurposing candidatePathway · 505(b)(2) · existing active ingredient, new indicationEvidence arm · Direct researchContradiction present

How to read thisThe summary above and the proposed mechanism are generated by the model from the sources it ingested, and are written as the model’s reasoning rather than established fact. Any figure quoted from MATRIX is a model-derived association score, not a clinical measurement. How far the published record backs this pair is carried by the score’s own rigor dimension and traced to verbatim sources at the foot of the page.

Hypothesized mechanism

Anti-androgens reduce androgen activity and raise SHBG, plausibly improving hirsutism in PCOS.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

How the score was reached, for this pair

The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 7 of 10 overall, a moderate reading, from a direct rated moderate in strength.

The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.

Direct research arm · anchors the headline7.0 / 10 · Moderate

Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).

Corroboration

All claims derive from a single systematic review and meta-analysis of RCTs; a single synthesis scores 1, not 2, since the pooled trials inside it do not count as independent replication. No additional independent sources are present.

1 / 2

Rigor

The source is a systematic review and meta-analysis of randomised controlled trials, which scores 2 on design. Results include weighted mean differences with 95% CIs and heterogeneity statistics.

2 / 2

Specificity

Both the intervention (anti-androgens + lifestyle) and the condition (PCOS) are named directly in the claims and source title. Outcomes such as hirsutism, SHBG, and fasting insulin are explicitly PCOS-relevant.

2 / 2

Plausibility

Anti-androgens plausibly improve hirsutism and SHBG in PCOS via reduced androgen activity, a mechanism implicit in the outcomes measured. No explicit mechanistic evidence is described in the claims, so it remains plausible rather than evidenced.

1 / 2

Consistency

Results are mixed: anti-androgens + lifestyle were superior to metformin + lifestyle for hirsutism and SHBG but NOT superior to placebo + lifestyle for the same outcomes. High heterogeneity (I2 = 74-76%) for several comparisons further limits consistency.

1 / 2

How the scoring rubric works, in general →

Layers not covered for this pair

Sex-specific pharmacokineticsNone on file

Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.

More on the sex-specific pharmacokinetics layer and its sources →

Cycle-phase dependenceNone on file

Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.

More on the cycle-phase layer and its sources →

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

1anti-androgens + lifestyle were superior to metformin + lifestyle for hirsutism PubMed · PMID 37583655 ↗
2anti-androgens + lifestyle were superior to metformin + lifestyle for hirsutism (weighted mean difference [WMD] [95% CI]: -1.59 [-3.06, -0.12], p = 0.03; I2 = 74%), SHBG (7.70 nmol/l [0.75, 14.66], p = 0.03; I2 = 0%) PubMed · PMID 37583655 ↗
3anti-androgens + lifestyle were superior to metformin + lifestyle for hirsutism (weighted mean difference [WMD] [95% CI]: -1.59 [-3.06, -0.12], p = 0.03; I2 = 74%), SHBG (7.70 nmol/l [0.75, 14.66], p = 0.03; I2 = 0%), fasting insulin PubMed · PMID 37583655 ↗
4anti-androgens + lifestyle were superior to metformin + lifestyle for hirsutism (weighted mean difference [WMD] [95% CI]: -1.59 [-3.06, -0.12], p = 0.03; I2 = 74%), SHBG (7.70 nmol/l [0.75, 14.66], p = 0.03; I2 = 0%), fasting insulin and fasting insulin: glucose ratio PubMed · PMID 37583655 ↗

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.

The primary sources and pipelines this evidence is drawn from →

← Back to the full index